Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Revenue of Poseida Therapeutics, Inc. (PSTX)
Revenue in 2023 (TTM): $64.7 M
According to Poseida Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $64.7 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Poseida Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $64.7 M | $59.09 M | $-129,504,000 | $-123,323,000 | $-123,430,000 |
| 2022 | $130.36 M | $125.19 M | $-57,088,000 | $-63,458,000 | $-64,002,000 |
| 2021 | $31.24 K | $-4,520,762 | $-121,616 | $-124,974 | $4.4 M |
| 2020 | $ | $-2,586,000 | $-126,269 | $-129,775 | $2.45 M |
| 2019 | $ | $-1,193,000 | $-75,098,000 | $-86,527,000 | $-92,639,000 |
| 2018 | $ | $-689,000 | $-40,689,000 | $-44,606,000 | $-44,404,000 |
| 2017 | $2.99 M | $2.99 M | $-20,880,000 | $-20,189,000 | $-19,662,000 |
| 2016 | $9.77 M | $9.77 M | $-5,229,000 | $-5,340,000 | $-4,575,000 |